Table 12.
Laboratory parameters before and after treatment in the safety-set
| Critical values | Pretreatment | Posttreatment | |||||
|---|---|---|---|---|---|---|---|
| Nitroxoline | Contols | p-value* | Nitroxoline | Contols | p-value* | ||
| Glucose (mg/dl) | < 55, >160 | 20/227 (8.8%) | 12/226 (5.3%) | 0.138 | 12/206 (5.8%) | 7/207 (3.4%) | 0.242 |
| Creatinine (mg/dl) | > 1.8 | 1/228 (0.4%) | 1/227 (0.4%) | 0.998 | 1/205 (0.5%) | 0/207 (0%) | - |
| Bilirubin (mg/dl) | < 0.1, >2.0 | 3/226 (1.3%) | 1/227 (0.4%) | 0.337 | 2/205 (1.0%) | 4/207 (1.9%) | 0.426 |
| SGOT –AST (U/l) | < 35, > = 150 | 224/226 (99.1%) | 225/226 (99.6%) | 0.570 | 203/205 (99.0%) | 206/207 (99.5%) | 0.564 |
| SGPT - ALT (U/l) | < 35, > = 150 | 222/226 (98.2%) | 225/226 (99.6%) | 0.212 | 204/205 (99.5%) | 207/207 (100%) | - |
| gamma-GT (U/l) | < 3, >38 | 9/227 (4.0%) | 10/226 (4.4%) | 0.807 | 9/205 (4.4%) | 6/207 (2.9%) | 0.412 |
| Sodium (mmol/l) | < 130, >150 | 8/228 (3.5%) | 6/226 (2.7%) | 0.603 | 11/205 (5.4%) | 5/207 (2.4%) | 0.132 |
| Potassium (mmol/l) | < 3.6, >6.0 | 22/228 (9.6%) | 19/226 (8.4%) | 0.628 | 19/205 (9.3%) | 12/206 (5.8%) | 0.229 |
| Calcium (mmol/l) | < 8, >11.5 | 229/229 (100%) | 227/227 (100%) | - | 206/206 (100%) | 206/206 (100%) | - |
| Hemoglobin (g/dl) | < 10, >17 | 0/227 (0%) | 0/219 (0%) | - | 1/201 (0.5%) | 2/204 (1.0%) | 0.582 |
| Hematocrit (%) | < 32, >47 | 25/227 (11.0%) | 33/220 (15.0%) | 0.197 | 20/201 (10.0%) | 33/204 (16.2%) | 0.065 |
| Erythrocytes (Mio/μl) | < 4, >5.1 | 29/227 (12.8%) | 14/220 (6.4%) | 0.024 | 22/201 (10.9%) | 26/205 (12.7%) | 0.588 |
| Leucocytes (Tsd/μl) | < 4, >11.3 | 25/227 (11.0%) | 21/220 (9.5%) | 0.605 | 13/200 (6.5%) | 16/204 (7.8%) | 0.614 |
| Neutrophiles (%) | < 39, >75 | 22/225 (9.8%) | 37/221 (16.7%) | 0.031 | 15/199 (7.5%) | 13/203 (6.4%) | 0.656 |
| Eosinophiles (%) | < 1, >10 | 10/223 (4.5%) | 19/219 (8.7%) | 0.080 | 11/199 (5.5%) | 8/203 (3.9%) | 0.399 |
| Basophiles (%) | 0, >15 | 38/222 (17.1%) | 47/220 (21.4%) | 0.257 | 29/199 (14.6%) | 38/203 (18.7%) | 0.266 |
| Lymphocytes (%) | < 10, >50 | 9/221 (4.1%) | 12/220 (5.5%) | 0.391 | 7/198 (3.5%) | 11/203 (5.4%) | 0.382 |
| Monocytes (%) | < 3, >25 | 7/223 (3.1%) | 14/220 (6.4%) | 0.117 | 9/199 (4.5%) | 6/203 (3.0%) | 0.410 |
| Retikulocytes (%) | < 0.5, >2 | 220/224 (98.2%) | 212/218 (97.2%) | 0.493 | 198/200 (99.0%) | 200/205 (97.6%) | 0.227 |
| Thrombocytes (Tsd/μl) | < 150, >450 | 11/225 (4.9%) | 8/218 (3.7%) | 0.529 | 10/201 (5.0%) | 8/204 (3.9%) | 0.608 |
| BSR (mm/1 h) | < 5, >11 | 134/203 (66.0%) | 124/202 (61.4%) | 0.343 | 106/179 (59.2%) | 114/187 (61.0%) | 0.756 |
| BSR (mm/2 h) | > 25 | 82/202 (40.6%) | 88/200 (44.0%) | 0.470 | 44/178 (24.7%) | 57/186 (30.6%) | 0.207 |
BSR-blood sedimentation rate.
*comparison of nitroxoline vs. controls, logistic regression with random center effect.